Opendata, web and dolomites

SPOT SIGNED

SPOT - Synthesis of Pretargeted Oncology Theranostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPOT project word cloud

Explore the words cloud of the SPOT project. It provides you a very rough idea of what is the project "SPOT" about.

lost    hyaluronic    acid    dbco    np    adenocarcinoma    pdac    chemotherapeutic    immunological    carriers    tested    tumor    pdca    reaction    zone    small    prognosis    trans    ideal    tco    conjugated    tissue    encapsulated    nps    vivo    outcome    groups    action    size    attached    poor    gemcitabine    nanoparticle    chances    cancer    sulfide    lactic    model    moieties    opponent    penetration    dibenzocyclooctyne    positive    surface    ab    drug    multivalent    probes    docetaxel    alginate    visualization    functionalized    noise    pretargeted    animal    fall    site    subsequently    shielding    preforming    silver    accumulation    click    drawbacks    tetrazine    bioorthogonal    clickable    intact    antibodies    overcome    electrospraying    gaining    capacities    healthy    diagnosis    delivering    undergo    xenografts    exclusive    ductal    additionally    azide    treatment    whereby    active    cycloaddition    spot    contrast    generation    fragments    imaging    deep    pancreatic    benefits    cyclooctene    injected    ligands    clearance    poly    extremely    ratio   

Project "SPOT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD COMPLUTENSE DE MADRID 

Organization address
address: AVENIDA DE SENECA 2
city: MADRID
postcode: 28040
website: http://www.ucm.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD COMPLUTENSE DE MADRID ES (MADRID) coordinator 160˙932.00

Map

 Project objective

To overcome size-related drawbacks of intact antibodies (Ab) for active tumor targeting, small but multivalent Ab-fragments, which fall in the “ideal tumor targeting zone”, are gaining increasing interest. However, the achieved benefits of Ab-fragments are lost when conjugated to imaging probes or drug carriers. Therefore, the SPOT action is going to focus on the generation of small Ab-fragments with highly specific targeting capacities and deep tissue penetration that are able to subsequently undergo a bioorthogonal click reaction at the tumor site. As cancer model, pancreatic ductal adenocarcinoma (PDAC), which currently still has an extremely poor prognosis, is going to be targeted. Two different click reaction will be evaluated: The cycloaddition between tetrazine and trans-cyclooctene (TCO) as well as azide and dibenzocyclooctyne (DBCO), whereby the Ab-fragments are functionalized with the TCO and DBCO groups. The opponent moieties are attached to alginate and hyaluronic acid-based ligands, which are subsequently introduced to the nanoparticle’s (NP) surface, additionally providing shielding from the immunological system. After the accumulation of the clickable Ab-fragments at the tumor site and their clearance from healthy tissue, the imaging or drug-delivering NPs with the opponent clickable moieties are injected, allowing for their exclusive accumulation at the pretargeted tumor site. For effective visualization of PDAC tissue, state-of-the-art silver sulfide NPs, with a high contrast-to-noise ratio and deep tissue imaging, are applied. The use of these NPs can be a significant step towards early PDCA diagnosis and therefore providing better chances for a positive treatment outcome. For the pretargeted drug-delivery approach, poly(lactic acid)-based NPs with encapsulated gemcitabine or docetaxel generated via electrospraying are going to be tested as a potential chemotherapeutic approach for PDAC, preforming small animal in vivo studies with PDAC xenografts.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPOT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPOT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

CP-FTmmW Aminogen (2020)

Chemistry and structure of aminogen radicals using chirped-pulse Fourier transform (sub)millimeter rotational spectroscopy

Read More  

TARGET SLEEP (2020)

Boosting motor learning through sleep and targeted memory reactivation in ageing and Parkinson’s disease

Read More